))
Why Private Equity firms are betting big on clinical research sites
Manage episode 400608868 series 3506216
Content provided by Darshan Kulkarni. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Darshan Kulkarni or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
We delve into the growing allure of clinical research sites and organizations for private equity firms. Backed by BPOC, these investments signify more than just single business deals; they are a testament to the increasing interest in fueling healthcare innovation and services.
As this trend gains momentum, thorough due diligence becomes crucial in navigating the complexities of these acquisitions. The Kulkarni Law Firm, specializing in Life Sciences law, plays a pivotal role in providing comprehensive support for regulatory compliance, contract reviews, and risk assessments. Daron emphasizes that these investments go beyond financial gains, contributing to the redefinition of the healthcare investment landscape.
The Kulkarni Law Firm keeps a watchful eye on the latest updates from the Department of Justice (DOJ), Office of Inspector General (OIG), and the Food and Drug Administration (FDA), ensuring that clients are well-informed and compliant.
Support the Show.
91 episodes
Share
